Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL

M. Nohtani, K. Vrzalikova, M. Ibrahim, JE. Powell, É. Fennell, S. Morgan, R. Grundy, K. McCarthy, S. Dewberry, J. Bouchal, K. Bouchalova, P. Kearns, PG. Murray

. 2022 ; 14 (17) : . [pub] 20220901

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023383

In this study, we have re-evaluated how EBV status influences clinical outcome. To accomplish this, we performed a literature review of all studies that have reported the effect of EBV status on patient outcome and also explored the effect of EBV positivity on outcome in a clinical trial of children with cHL from the UK. Our literature review revealed that almost all studies of older adults/elderly patients have reported an adverse effect of an EBV-positive status on outcome. In younger adults with cHL, EBV-positive status was either associated with a moderate beneficial effect or no effect, and the results in children and adolescents were conflicting. Our own analysis of a series of 166 children with cHL revealed no difference in overall survival between EBV-positive and EBV-negative groups (p = 0.942, log rank test). However, EBV-positive subjects had significantly longer event-free survival (p = 0.0026). Positive latent membrane protein 1 (LMP1) status was associated with a significantly lower risk of treatment failure in a Cox regression model (HR = 0.21, p = 0.005). In models that controlled for age, gender, and stage, EBV status had a similar effect size and statistical significance. This study highlights the age-related impact of EBV status on outcome in cHL patients and suggests different pathogenic effects of EBV at different stages of life.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023383
003      
CZ-PrNML
005      
20221031095232.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14174297 $2 doi
035    __
$a (PubMed)36077832
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Nohtani, Mahdi $u Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland $u School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland $1 0000000286253812
245    10
$a Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL / $c M. Nohtani, K. Vrzalikova, M. Ibrahim, JE. Powell, É. Fennell, S. Morgan, R. Grundy, K. McCarthy, S. Dewberry, J. Bouchal, K. Bouchalova, P. Kearns, PG. Murray
520    9_
$a In this study, we have re-evaluated how EBV status influences clinical outcome. To accomplish this, we performed a literature review of all studies that have reported the effect of EBV status on patient outcome and also explored the effect of EBV positivity on outcome in a clinical trial of children with cHL from the UK. Our literature review revealed that almost all studies of older adults/elderly patients have reported an adverse effect of an EBV-positive status on outcome. In younger adults with cHL, EBV-positive status was either associated with a moderate beneficial effect or no effect, and the results in children and adolescents were conflicting. Our own analysis of a series of 166 children with cHL revealed no difference in overall survival between EBV-positive and EBV-negative groups (p = 0.942, log rank test). However, EBV-positive subjects had significantly longer event-free survival (p = 0.0026). Positive latent membrane protein 1 (LMP1) status was associated with a significantly lower risk of treatment failure in a Cox regression model (HR = 0.21, p = 0.005). In models that controlled for age, gender, and stage, EBV status had a similar effect size and statistical significance. This study highlights the age-related impact of EBV status on outcome in cHL patients and suggests different pathogenic effects of EBV at different stages of life.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vrzalikova, Katerina $u Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
700    1_
$a Ibrahim, Maha $u Cancer Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut 71526, Egypt
700    1_
$a Powell, Judith E $u Department of Public Health & Epidemiology, University of Birmingham, Birmingham B15 2TT, UK
700    1_
$a Fennell, Éanna $u Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland $u School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland $1 0000000212803439
700    1_
$a Morgan, Susan $u Department of Histopathology, Sheffield Teaching Hospitals, Sheffield S10 2JF, UK
700    1_
$a Grundy, Richard $u Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK
700    1_
$a McCarthy, Keith $u Department of Histopathology, Wye Valley NHS Trust, Hereford HR1 2ER, UK
700    1_
$a Dewberry, Sarah $u Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, College of Medicine and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
700    1_
$a Bouchal, Jan $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University, 77900 Olomouc, Czech Republic $1 0000000348421720
700    1_
$a Bouchalova, Katerina $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University, 77900 Olomouc, Czech Republic
700    1_
$a Kearns, Pamela $u Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, College of Medicine and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
700    1_
$a Murray, Paul G $u School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University, 77900 Olomouc, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 17 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36077832 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095230 $b ABA008
999    __
$a ind $b bmc $g 1853840 $s 1174671
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 17 $e 20220901 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Možnosti archivace